Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 1934Neoplasms 1387Carcinoma, Non-Small-Cell Lung 1328Prostatic Neoplasms 1072Multiple Myeloma 857Leukemia, Myeloid, Acute 764Neoplasm Metastasis 693Colorectal Neoplasms 679Melanoma 671Lung Neoplasms 666Lymphoma 656Leukemia 592Lymphoma, Non-Hodgkin 588Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 522Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 473Recurrence 466Myelodysplastic Syndromes 422Lymphoma, Follicular 407Head and Neck Neoplasms 402Carcinoma, Renal Cell 377Glioblastoma 376Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 371Hodgkin Disease 352Carcinoma, Hepatocellular 325Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

pegfilgrastim 4balugrastim 2NPI 2358 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × Chemotherapy-induced Neutropenia × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

NCT00837265 2024-04-03

NEUGR-002

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2/3 Completed
334 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡